[A clinical study to determine the optimal dosage of ST-679 in the treatment of rheumatic diseases].
A study was performed with 60 patients, affected by acute phase rheumatological pathology, in order to determine the optimum posology of ST-679 administered orally. The 60 patients were divided into 4 groups: 3 treated with ST-679 at different dosages (group 1 = 600 mg/die; group 2 = 1200 mg/die; group 3 = 1800 mg/die) and one with placebo (group 4 = 600 mg/die). The highest dosage employed (1800 mg/die) performs an excellent therapeutical activity which is equivalent to that at the 1200 mg in reducing pain symptomatology, but on the average less tolerated. The 600 mg dosage was less efficacious with respect to the two higher doses.